We build pioneering companies and advance their pipeline to make a positive impact on health and well-being.

Mission

We invest in and build companies with pioneering pharmaceutical and biotech projects or adjacent capabilities. We differentiate ourselves by using our network, expertise and resources to achieve long-term success for our companies. We have the utmost respect for all our stakeholders and strive to be described by them as a great partner.

Flerie's story

Flerie Insights

Professor Carel le Roux

Professor of Metabolic Medicine, School of Medicine, University College Dublin
Senior Clinician, St Vincent’s Private Hospital

In recent decades, the prevalence of obesity has increased dramatically worldwide, posing serious challenges to public health, but traditional definitions and treatments for obesity often fall short. As science moves beyond weight loss there is a shift toward understanding obesity as a complex, chronic disease with diverse causes and responses to treatment.

In this episode, Dr. Ted Fjällman speaks with Professor Carel le Roux about the evolving landscape of obesity care, exploring current and future treatment options, common misconceptions, and highlighting the importance of treating the disease of obesity rather than only focusing on weight loss.

Professor le Roux is an eminent leader in the fast-changing fields of obesity and diabetes and his views are not only timely for practicing clinicians but for anyone investing their time or money in diabesity.

Professor Lars Lund

Professor of Cardiology, Department of Medicine, Karolinska Institutet
Senior Physician, Karolinska University Hospital

Heart failure is a growing global health challenge, yet significant gaps remain in its treatment. With millions of patients suffering from reduced quality of life and high mortality rates, there is an urgent need to innovate and transform care pathways.

In this episode, Dr. Ted Fjällman and Professor Lars Lund, discuss the critical gaps in the treatment of heart failure. They discuss recent advancements, the challenges facing patients and clinicians, and the potential for innovative therapies to transform care and improve outcomes for millions affected worldwide.

Professor Lund is a shareholder in AnaCardio.

Tim Opler

Ph.D. in Economics, University of California, Los Angeles

Managing Director in Stifel’s Global Healthcare Group

The past few years have been challenging for many life science companies, both in the private setting but also those on public markets, and the IPO window for new listings has been essentially closed. The industry is dependent on the availability of capital as well as the risk appetite, both impacted by macroeconomic factors. Deal-making and M&A (merges and acquisitions) with pharma are the lifeblood of the industry.

In this episode, Ted Fjällman speaks to Tim Opler. Having taken part in more than 150 transactions with a total value of $100 billion, Tim shares his expertise and elaborates on different ways of financing innovation, a booming obesity field, and how patents are currently central to gaining a competitive advantage, but not the only measure.